Tamoxifen benefits and CYP2D6 testing in women with hormone receptor-positive breast cancer.
作者： Marcelle Kaplan , Suzanne M. Mahon
关键词: Oncology 、 Clinical trial 、 Pharmacogenomics 、 Breast cancer 、 Tamoxifen 、 Hormone receptor 、 Hormone 、 Medicine 、 CYP2D6 、 Internal medicine 、 Targeted therapy
摘要: Cancer intervention strategies have been increasingly focused on developing therapies that are personalized and tailored to each individual's unique genetic profile. Evolving understanding of the metabolism pharmacogenomics tamoxifen, an early example targeted therapy for women with hormone receptor-positive breast cancer, has created decision-making challenges healthcare providers their patients. This article reviews pharmacology genetics physiology CYP2D6 enzyme system important effects tamoxifen metabolism, subset data analyses from large controlled, clinical trials cast new light previously held beliefs about utility genotyping predicting effectiveness improved cancer outcomes in early-stage, cancer.
metapress.com参考文章(31)
Christine L.H. Snozek, Dennis J. O'Kane, Alicia Algeciras-Schimnich, Pharmacogenetics of Solid Tumors: Directed Therapy in Breast, Lung, and Colorectal Cancer The Journal of Molecular Diagnostics. ,vol. 11, pp. 381- 389 ,(2009) , 10.2353/JMOLDX.2009.090003
Jill Kolesar, Cindy Gaston, Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer. Clinical advances in hematology & oncology. ,vol. 6, pp. 825- 833 ,(2008)
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer The New England Journal of Medicine. ,vol. 353, pp. 2747- 2757 ,(2005) , 10.1056/NEJMOA052258
Alan H. B. Wu, Wendy Lorizio, Simone Tchu, Kara Lynch, Roy Gerona, Wuyang Ji, Weiming Ruan, Kathryn J. Ruddy, Stephen D. Desantis, Harold J. Burstein, Elad Ziv, Estimation of tamoxifen metabolite concentrations in the blood of breast cancer patients through CYP2D6 genotype activity score Breast Cancer Research and Treatment. ,vol. 133, pp. 677- 683 ,(2012) , 10.1007/S10549-012-1963-2
Alastair M Thompson, Andrea Johnson, Philip Quinlan, Grantland Hillman, Marcel Fontecha, Susan E Bray, Colin A Purdie, Lee B Jordan, Roberta Ferraldeschi, Ayshe Latif, Kirsten D Hadfield, Robert B Clarke, Linda Ashcroft, D Gareth Evans, Anthony Howell, Michele Nikoloff, Jeffrey Lawrence, William G Newman, None, Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy Breast Cancer Research and Treatment. ,vol. 125, pp. 279- 287 ,(2011) , 10.1007/S10549-010-1139-X
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. The New England Journal of Medicine. ,vol. 361, pp. 766- 776 ,(2009) , 10.1056/NEJMOA0810818
Caitlin C. Murphy, L. Kay Bartholomew, Melissa Y. Carpentier, Shirley M. Bluethmann, Sally W. Vernon, Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Research and Treatment. ,vol. 134, pp. 459- 478 ,(2012) , 10.1007/S10549-012-2114-5
Kostandinos Sideras, James N. Ingle, Matthew M. Ames, Charles L. Loprinzi, David P. Mrazek, John L. Black, Richard M. Weinshilboum, John R. Hawse, Thomas C. Spelsberg, Matthew P. Goetz, Coprescription of Tamoxifen and Medications That Inhibit CYP2D6 Journal of Clinical Oncology. ,vol. 28, pp. 2768- 2776 ,(2010) , 10.1200/JCO.2009.23.8931
W. L. McGuire, K. B. Horwitz, O. H. Pearson, A. Segaloff, Current status of estrogen and progesterone receptors in breast cancer Cancer. ,vol. 39, pp. 2934- 2947 ,(1977) , 10.1002/1097-0142(197706)39:6<2934::AID-CNCR2820390680>3.0.CO;2-P
C. M Kelly, D. N Juurlink, T. Gomes, M. Duong-Hua, K. I Pritchard, P. C Austin, L. F Paszat, Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study BMJ. ,vol. 340, ,(2010) , 10.1136/BMJ.C693